# Exploring the temporal relationship between psychosocial risk factors and recurrent ischemic priapism

## TL;DR

This study explores whether psychosocial and substance use factors come before or after recurrent ischemic priapism, finding a complex, possibly bidirectional relationship.

## Contribution

The study is the first to investigate the temporal relationship between psychosocial risk factors and the onset of recurrent ischemic priapism.

## Key findings

- No statistically significant difference was found in the proportion of risk factors developing before or after the onset of RIP.
- In the SCD sub-analysis, more patients started psychiatric medication after RIP onset, though not statistically significant.
- The study suggests a bidirectional relationship between RIP and psychosocial factors, emphasizing the need for mental health screening.

## Abstract

The development of recurrent ischemic priapism (RIP) is associated with mental health disorders, psychiatric medications, and substance use, but the temporal relationship between the onset of RIP and the development of these risk factors is poorly understood.

This study aimed to investigate the chronology of psychosocial and substance use risk factors relative to the initial clinical presentation of RIP.

We conducted a retrospective cohort study of 73 adult patients diagnosed with RIP at a single academic center, identified via manual chart review of the electronic health record. Patients presenting with RIP between 2004 and 2020 were included, with data collection extending to 2025 to ensure a minimum follow-up of nearly 5 years for all participants to minimize censoring bias and capture delayed risk factor onset.

The date of the first RIP presentation (index event) was compared to the first documented date of several risk factors, including anxiety, depression, psychiatric medication use, and substance use.

In the overall cohort, there was no statistically significant difference in the proportion of any risk factor developing before versus after the onset of RIP. Further, in a sub-analysis of 35 patients with sickle cell disease (SCD), a higher proportion of patients initiated psychiatric medication after the onset of RIP, although this was not statistically significant (P = .0522). No other factors reached statistical significance in the SCD sub-analysis.

The findings suggest that RIP may be a psychologically traumatic event that contributes to the development of the same psychosocial risk factors it is associated with.

The primary strength of this study is its novel investigation into the temporal relationship between RIP and psychosocial risk factors, supported by a design that ensured a minimum follow-up period of over 4 years for all participants. Limitations are primarily related to its retrospective, single-center chart-review design.

Our findings suggest a complex, potentially bidirectional relationship that highlights the need for integrated mental health screening for all patients with RIP, particularly for the high-risk SCD population.